Rznomics announced on the 14th that they signed an MOU for joint research with the University of Missouri in the United States.
Under the agreement, two sides will cooperate in all areas of research for the development of gene therapy products, including ribonucleic acid (RNA) editing, establishment of human gene transduction animal models, preclinical trials and clinical research.
The MOU is expected to promote mutual exchange of human and material resources and technological development.
The University of Missouri, established in 1839, is a state university that is prominent in the fields of agriculture, veterinary medicine, medicine, and pharmacy. Which recently, they shared their interest in gene therapy research.
Seongwook Lee, CEO of Rznomics, stated, "By combining the RNA editing platform technology possessed by Rznomics and the research infrastructure of the University of Missouri, we will be able to strengthen our competitiveness in the field of RNA-based gene therapy research. We will leap forward as a global gene therapy company.”